Clinical trials: Cirrhosis Portal
Gastroesophageal Varices, Cirrhosis
The Effect of Hepatic Vein Pressure Gradient(HVPG)-Guided Therapy in Cirrhotic Patients With Esophagogastric Varices
The purpose of the study is to compare the effect of HVPG-guided individualized therapy and non-HVPG guided traditional therapy in cirrhotic patients for secondary prophylaxis.
- Trial name
- NCT02638415
- Testing
- HVPG-guided therapy, routine therapy, Carvedilol
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatic Fibrosis
QTc Assessment in a Single-Dose Study of Hydronidone Capsules
This study was designed with three dose cohorts (A1-A3): a 90 mg cohort, a 270 mg cohort, and a 540 mg cohort. Each cohort enrolled 16 healthy Chinese participants, with 12 receiving the investigational product Hydronidone…
- Trial name
- NCT07263152
- Testing
- Hydronidone
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Liver Cirrhosis, Hepatic Encephalopathy
Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement
The investigators wish to investigate how the Continuous Reaction Time (CRT) method can be used in the diagnosis and monitoring of covert hepatic encephalopathy (cHE)in patients with cirrhosis of the liver.
- Trial name
- NCT01773538
- Testing
- Lactulose and rifaximin, Branched Chain amino acids
- Where
- 2 sites in Denmark
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Mette Munk Lauridsen
Cirrhosis
Evaluation of the Role of Plasma Biomarkers in the Development of Decompensation in Patients With Cirrhosis .
This is a single-center and prospective study to identify specific biomarker in order to predict development of decompensation in cirrhotic patients. The duration of the study is 36 months and it provides a cohort of 200 patients.
- Trial name
- NCT03084185
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- University of Modena and Reggio Emilia
Liver Cancer, Hepatocellular Carcinoma
Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer
Cirrhotic patients undergoing hepatic resection have a mortality rate near 10%, and 30 to 70% of them develop severe complications. These failures are mainly due to hepatic insufficiency.
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Cirrhosis, Liver Fibrosis
- Trial name
- IMPACT (NCT00151671)
- Testing
- Oral Impact®
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Rennes University Hospital
Covert Hepatic Encephalopathy
GELSECTAN® and Covert Hepatic Encephalopathy
Randomized crossover pilot clinical trial in which 10 cirrhotic patients with covert hepatic encephalopathy (CHE) will be assigned to take GELSECTAN® (TID) or placebo for 30 days.
- Trial name
- GELSECTAN (NCT05189834)
- Testing
- Gelsectan
- Where
- Spain
- Sponsor
- Consorci Sanitari de l'Alt Penedès i Garraf
Portal Hypertension
A Novel Imaging Based Quantitative Model-aided Detection of Portal Hypertension in Patients With Cirrhosis (CHESS2104)
How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis.
- Trial name
- NCT05068492
- Testing
- CT, MRI, HVPG
- Volunteers
- 2,000 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Carcinoma, Hepatocellular, Cirrhosis
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver.
- Trial name
- PREMIUM (NCT05486572)
- Testing
- Abbreviated Magnetic Resonance Imaging with serum AFP, Abdominal Ultrasound Screening with serum AFP
- Where
- 34 sites in United States
- Volunteers
- 4,700 people
- Sponsor
- VA Office of Research and Development
Cirrhosis
Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis
The methacetin breath test (MBT) is a non-invasive liver function test which measures the ability of the liver to metabolize a tracer dose of a compound to carbon dioxide, which is exhaled.
- Trial name
- NCT01157845
- Testing
- BreathID (Methacetin breath test)
- Where
- 4 sites in United States, Israel
- Volunteers
- 165 people
- Sponsor
- Virginia Commonwealth University
Acute on Chronic Liver Failure, Variceal Hemorrhage
Goal-Directed Hemostatic Resuscitation Trial in ACLF Induced Coagulopathy
In this project, we plan to evaluate whether a new, rotational thromboelastometry-guided algorithm (ROTEM) to guide hemostatic resuscitation decreases the use of allogeneic blood products, the total amount of bleeding…
- Conditions
- Acute on Chronic Liver Failure, Variceal Hemorrhage, Cirrhosis, Liver, Thromboelastometry
- Trial name
- GOODHEART-ACLF (NCT05124041)
- Testing
- Rotational thromboelastometry
- Where
- India
- Volunteers
- 262 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Fatty Liver Disease, Fatty Liver
Impact of Time-restricted Feeding in NAFLD
This is a randomised controlled study of patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Patients will be trained according to the 10 rules of a healthy nutrition according to the German Association for Nutrition (DGE).
- Conditions
- Fatty Liver Disease, Fatty Liver, Fatty Liver, Nonalcoholic
- Trial name
- NAFLD-TRF (NCT05220956)
- Testing
- Intermittent fasting, DGE diet
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Johannes Gutenberg University Mainz
Nonalcoholic Fatty Liver, Osteoporosis, Postmenopausal
Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is a chronic, metabolic liver disease that is closely related to obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) in a bidirectional mode.
- Trial name
- OsteoNAFLD (NCT05493761)
- Testing
- Denosumab, Alendronate Sodium
- Where
- 3 sites in Greece
- Volunteers
- 72 people
- Sponsor
- Aristotle University Of Thessaloniki
Liver Failure, Thrombocytopenia
Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia
End stage liver disease is prone to thrombocytopenia. This study is a multi-center, randomized, prospective, randomized controlled Phase IV Clinical trial to discuss the Efficacy and Safety of Avatrombopag in Patients with…
- Conditions
- Liver Failure, Thrombocytopenia, Decompensated Cirrhosis
- Trial name
- NCT04906083
- Testing
- Avatrombopag, Standard medical treatment
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Tongji Hospital
Cirrhosis, Liver, Splenectomy; Status
Effect of LSD on Renal Function in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)
Patients with liver cirrhosis often have impaired or at-risk kidney function due to the close link between liver and kidney (hepatorenal syndrome).
- Conditions
- Cirrhosis, Liver, Splenectomy; Status, Renal Function Abnormal, Portal Hypertension
- Trial name
- LSD-RFPH (NCT07585786)
- Volunteers
- 30 people
- Sponsor
- Northern Jiangsu People's Hospital
Cirrhosis, Portal Hypertension
Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis
The aim of this study is to investigate the effects of spironolactone on liver fibrosis progression and portal pressure gradient in patients with advanced chronic liver disease.
- Trial name
- FP-PH (NCT02907749)
- Testing
- Spironolactone and carvedilol, Carvedilol
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Changqing Yang
Portal Hypertension Related to Cirrhosis
AI-guided TIPS Procedure
The goal of this clinical trial is to learn if transjugular intrahepatic portosystemic shunt (TIPS)-guided AI model can guide TIPS procedure in adults better than conventional TIPS procedure (artificially blinded TIPS).
- Trial name
- NCT06837974
- Testing
- AI guided TIPS, Artificially blinded TIPS
- Where
- 3 sites in China
- Volunteers
- 180 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hypertension, Portal
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Study GT 026 is a Phase 2, multicenter, parallel group, North American, randomized, placebo controlled, double blind study. This study will enroll subjects with portal hypertension (HVPG greater than or equal to 6 mm Hg) who also…
- Trial name
- NASH-CX (NCT02462967)
- Testing
- GR-MD-02
- Where
- 46 sites in United States
- Volunteers
- 162 people
- Sponsor
- Galectin Therapeutics Inc.
Portal Pressure Gradient (PPG) Measurement Guided by Endoscopic Ultrasound (EUS), Hepatic Cirrhosis
Evaluation of the Efficacy and Safety of Portal Pressure Gradient (PPG) Measurement Guided by Endoscopic Ultrasound (EUS) in the Therapeutic Algorithm of Patients with Liver Cirrhosis.
The development of Clinical significant PH (CSPH) is a major driver of complications. PPG is the strongest predictor of decompensation .
- Trial name
- GPP-USE (NCT06664307)
- Where
- Spain
- Volunteers
- 35 people
- Sponsor
- Hospital Universitario Virgen Macarena
Liver Cirrhosis
A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients
To evaluate the safety of IV conivaptan in stable euvolemic or hypervolemic cirrhotic patients, and to characterize the effects of IV conivaptan on the hepatic hemodynamic response in patients with cirrhosis.
- Trial name
- NCT00592475
- Testing
- conivaptan
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Cumberland Pharmaceuticals
Liver Cirrhosis, Portal Hypertension
Endoscopic Ruler for the Assessment of Variceal Bleeding Risks (CHESS2005)
The presence of varices is a serious complication of portal hypertension in liver disease. To prevent variceal haemorrhage, screening and surveillance aims to detect high-risk varices related to varices size and determine the…
- Conditions
- Liver Cirrhosis, Portal Hypertension, Gastroesophageal Varices
- Trial name
- NCT04639323
- Testing
- Endoscopic ruler
- Where
- 7 sites in China
- Volunteers
- 266 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province